ROMOSOZUMAB AS A NEW THERAPEUTIC OPTION IN POSTMENOPAUSAL OSTEOPOROSIS WITH VERY HIGH FRACTURE RISK: A CASE REPORT

Katarzyna Gołojuch; Patrycja Major; Przemysław Borowy; Jakub Smyk; Alicja Kamińska

doi:10.5114/hpc.2024.146121

eISSN: 2354-0265
ISSN: 2353-6942

Health Problems of Civilization Physical activity: diseases and issues recognized by the WHO

Bieżący numer Archiwum Online first O czasopiśmie Rada naukowa Recenzenci Bazy indeksacyjne Kontakt Zasady publikacji prac Opłaty publikacyjne Standardy etyczne i procedury

Panel Redakcyjny

Zgłaszanie i recenzowanie prac online

Wyszukiwanie

Zasady redakcyjne

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Otwarty dostęp

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

Opis przypadku

ROMOSOZUMAB AS A NEW THERAPEUTIC OPTION IN POSTMENOPAUSAL OSTEOPOROSIS WITH VERY HIGH FRACTURE RISK: A CASE REPORT

Katarzyna Gołojuch

¹

,

Patrycja Major

²

,

Przemysław Borowy

^{3, 4}

,

Jakub Smyk

¹

,

Alicja Kamińska

⁵

Ludwik Rydygier Memorial Hospital, Kraków, Poland
5th Military Clinical Hospital in Kraków, Kraków, Poland
Department of Rheumatology and Immunology, J. Dietl Hospital, Krakow, Poland
Department of Rheumatology and Immunology, Andrzej Frycz-Modrzewski Kraków University, Kraków, Poland
Stefan Żeromski Specialist Hospital, Kraków, Poland

Health Prob Civil.

DOI: https://doi.org/10.5114/hpc.2024.146121

Data publikacji online: 2025/01/08

Plik artykułu:

- Kamińska et al.pdf [0.47 MB]

Pobierz cytowanie

Metryki PlumX:

1. Alimy AR, Anastasilakis AD, Carey JJ, D'Oronzo S, Naciu AM, Paccou J, et al. Conservative Treatments in the Management of Acute Painful Vertebral Compression Fractures: a Systematic Review and Network Meta-Analysis. JAMA Netw Open. 2024; 7(9): e2432041. https://doi.org/10.1001/jamanetworkopen.2024.32041

2. Spiegl U, Bork H, Grüninger S, Maus U, Osterhoff G, Scheyerer MJ, et al. Osteoporotic Fractures of the Thoracic and Lumbar Vertebrae: Diagnosis and Conservative Treatment. Dtsch Arztebl Int. 2021; 118(40): 670-677. https://doi.org/10.3238/arztebl.m2021.0295

3. Prost S, Pesenti S, Fuentes S, Tropiano P, Blondel B. Treatment of Osteoporotic Vertebral Fractures. Orthop Traumatol Surg Res. 2021; 107(1S): 102779. https://doi.org/10.1016/j.otsr.2020.102779

4. Singh S, Dutta S, Khasbage S, Kumar T, Sachin J, Sharma J, et al. A Systematic Review and Meta-Analysis of Efficacy and Safety of Romosozumab in Postmenopausal Osteoporosis. Osteoporos Int. 2022; 33(1): 1-12. https://doi.org/10.1007/s00198-021-06095-y

5. Głuszko P, Sewerynek E, Misiorowski W, Konstantynowicz J, Marcinowska-Suchowierska E, Blicharski T, et al. Guidelines for the Diagnosis and Management of Osteoporosis in Poland. Update 2022. Endokrynol Pol. 2023; 74(1): 5-15. https://doi.org/10.5603/EP.a2023.0012

6. McClung MR, Brown JP, Diez-Perez A, Resch H, Caminis J, Meisner P, et al. Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: a Randomized, Double-Blind, Phase 2, Parallel Group Study. J Bone Miner Res. 2018; 33(8): 1397-1406. https://doi.org/10.1002/jbmr.3452

7. LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, el al. The Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2022; 33(10): 2049-2102. https://doi.org/10.1007/s00198-021-05900-y

8. Geusens P, Feldman R, Oates M, Thomas T, Makras P, Jakob F, et al. Romosozumab Reduces Incidence of New Vertebral Fractures across Severity Grades among Postmenopausal Women with Osteoporosis. Bone. 2022; 154: 116209. https://doi.org/10.1016/j.bone.2021.116209

9. Horikawa A, Kasukawa Y, Hongo M, Sano A, Miyakoshi N. The Effects of Switch Therapy in Osteoporosis Treatment after Romosozumab after Comparing with Prior Treatment. J Osteoporos. 2024; 2024: 2144527. https://doi.org/10.1155/2024/2144527

Copyright: © 2025 Pope John Paul II State School of Higher Education in Biała Podlaska. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

ROMOSOZUMAB AS A NEW THERAPEUTIC OPTION IN POSTMENOPAUSAL OSTEOPOROSIS WITH VERY HIGH FRACTURE RISK: A CASE REPORT

Katarzyna Gołojuch 1 , Patrycja Major 2 , Przemysław Borowy 3, 4 , Jakub Smyk 1 , Alicja Kamińska 5

Katarzyna Gołojuch

¹

,

Patrycja Major

²

,

Przemysław Borowy

^{3, 4}

,

Jakub Smyk

¹

,

Alicja Kamińska

⁵